It should be noticed, though, that although CRC is not yet an approved indication of any PARP inhibitor, several manuscripts have highlighted their potential, in particular in combination with DNA damaging agents such as irinotecan (Davidson et al., 2013; Genther Williams et al., 2015; Augustine et al., 2019), 5-fluorouracil and oxaliplatin (Jarrar et al., 2019), PI3K inhibitors in combination with anti-CTLA4 immunotherapy and X-ray radiation (Landry et al., 2020), p53 inhibitors (idasanutlin or pifithirin-β) (Smeby et al., 2020) or ATM inhibitors (Wang et al., 2017a). The gene discussed is TP53; the disease is colorectal carcinoma.